SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 40.48% in the sales to Rs. 7399.60 millions was observed for the quarter ended September 2022. The sales figure stood at Rs. 5267.30 millions during the year-ago period.Net profit stood at Rs. 977.20  millions  compared to Rs. 884.00 millions in the corresponding previous quarter,high by 10.54%.Operating Profit saw a handsome growth to 1675.10 millions from 1342.40 millions in the quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 7399.60 5267.30 40.48 14560.90 10730.30 35.70 21898.76 18919.95 15.74
Other Income 17.20 195.60 -91.21 22.30 324.40 -93.13 386.14 1118.89 -65.49
PBIDT 1675.10 1342.40 24.78 3360.00 3054.30 10.01 5475.24 6682.54 -18.07
Interest 76.00 11.80 544.07 133.90 20.70 546.86 49.49 71.92 -31.19
PBDT 1599.10 1330.60 20.18 3226.10 3033.60 6.35 5425.75 6610.62 -17.92
Depreciation 277.10 154.00 79.94 534.00 328.80 62.41 712.82 673.55 5.83
PBT 1322.00 1176.60 12.36 2692.10 2704.80 -0.47 4712.93 5937.07 -20.62
TAX 344.80 292.60 17.84 702.00 667.70 5.14 1102.91 1466.23 -24.78
Deferred Tax 111.30 22.60 392.48 228.50 17.70 1190.96 -122.09 91.23 -233.83
PAT 977.20 884.00 10.54 1990.10 2037.10 -2.31 3610.02 4470.84 -19.25
Equity 154.70 154.60 0.06 154.70 154.60 0.06 154.56 154.56 0.00
PBIDTM(%) 22.64 25.49 -11.17 23.08 28.46 -18.93 25.00 35.32 -29.21

JB Chem & Pharma Share Price

1985.50 10.80 (0.55%)
17-Apr-2026 13:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.05
Dr. Reddys Lab 1229.60
Cipla 1236.50
Zydus Lifesciences 945.00
Lupin 2307.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×